invIOs Initiates Patient Enrolment in the P-Ib Trial (PALINDROM) of APN401 for Solid Tumors
Shots:
- The patient enrolment has been initiated for a P-Ib trial (PALINDROM) to evaluate the optimal dosage of APN401 in ~12 patients across four clinics. The trial is conducted in Austria with 2 GMP-compliant manufacturing sites in Vienna and Linz while enrolment is expected to be completed at the end of 2023
- The 1EP of the study is to define & confirm the safety profile of APN401 while the 2EPs incl. measures of immunological & anti-tumor activity, ORR & PFS as well as analysis of relevant biomarkers. The trial will open the way for bigger P-II investigation with early lines of treatment and as a combination therapy by establishing MTD and/or MMD of APN401
- invIOs awarded ~45% funding of trial costs by Austrian Research Promotion Agency (FFG) to support P-Ib RP2D trial; also awarded grant funding to advance INV451 against lung cancer with Medical University of Innsbruck
Ref: Globenewswire | Image: invIOs
Related News:- Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
